Global bond yields have moved lower as large buyback programs and liquidity support ease pressure on long dated debt. That gives long term themes like psychedelic medicine more breathing room, since funding costs can be a critical swing factor for clinical pipelines. This article highlights three revenue generating psychedelics stocks from our screener and explains why this niche could matter for a diversified portfolio over the next market cycle.

The stocks covered below are just a starting sample, and the full screen surfaced 1 more psychedelics company with an equally compelling revenue story that is not included in this article. If you want to identify and analyze the highest conviction opportunities in this niche, head straight to the Psychedelics companies generating revenue screener.

Optimi Health (OPTH)

Overview: Optimi Health is a Canadian drug manufacturer that produces and supplies finished MDMA and psilocybin products, other psychedelic substances and functional mushroom supplements to clinics, pharmacies, clinical trials and wellness customers, supported by its own farming, processing and online distribution channels.

Market Cap: US$27.5 million

Optimi Health has caught investor attention because it sits at the manufacturing end of the psychedelics value chain, already supplying psilocybin capsules and biomass into clinical trials in Australia and the UK while expanding formats like microdose products. Forecast revenue growth of 78.4% a year points to strong expectations for demand, yet the business is still very small at about CA$176k in sales and continues to report widening losses and heavy reliance on external funding, including large recent equity facilities. That mix of commercial traction and financial strain, plus higher than peer P/B and a volatile share price, makes Optimi a high risk play that some investors see as a direct way to get exposure to regulated psychedelic drug production as the sector matures.

The most followed Narrative on the Simply Wall St Community centres on Optimi Health’s potential valuation disconnect. The bullish thesis is that, unlike many psychedelic peers still reliant on clinical trials and future regulatory approvals, Optimi is already manufacturing and supplying MDMA and psilocybin into a live commercial market in Australia. Supporters argue that its existing GMP manufacturing infrastructure, potential operating leverage as patient volumes grow, and exposure to future opportunities in markets such as the US could leave the company undervalued relative to larger, but largely pre-revenue, psychedelic peers.

Optimi Health’s revenue story and tiny current scale hint at an inflection point that many investors may be underestimating. See how the analyst forecasts for Optimi Health could reshape expectations or expose a crucial pressure point.

AtaiBeckley (ATAI)

Overview: AtaiBeckley is a clinical stage biopharmaceutical company developing psychedelic and non psychedelic treatments for mental health conditions such as treatment resistant depression, alcohol use disorder, schizophrenia related cognitive impairment, social anxiety and major depressive disorder across the US, Germany and Canada.

Operations: The company currently generates about US$4 million in revenue from its business of identifying and advancing mental health treatments.

Market Cap: US$2.7b

Investors watching AtaiBeckley are weighing a rare mix of late stage psychedelic drug programs, tiny current revenue and a proposed takeover by Eli Lilly at up to US 4 million and losses remain heavy, so the real focus is on the value of its clinical assets and Lilly’s willingness to pay around US$2.8b upfront subject to deal conditions. The stock has been volatile, the P/B multiple is high and shareholders have faced dilution, which raises questions about downside if the deal stalls. With Phase 2 data readouts and a shareholder vote still ahead, this story is far from settled for psychedelics focused investors.

AtaiBeckley’s mix of late stage trials and a proposed multi billion dollar Lilly offer has investors asking what the market is really pricing in. Get the full picture in the 1 key reward and 4 important warning signs (1 is major!).

Cybin (HELP)

Overview: Cybin, which operates as Helus Pharma, is a clinical stage pharmaceutical company developing psychedelic based therapies like HLP003 and HLP004 for major depressive disorder and generalized anxiety disorder, alongside early stage compounds targeting broader central nervous system conditions.

Market Cap: US$730 million

Cybin provides exposure to late stage psychedelic drug candidates at a moment when its HLP003 psilocybin analog is already in Phase 3 for major depressive disorder and HLP004 is in Phase 2 for generalized anxiety disorder, both aimed at large treatment gaps. Clinic friendly trial designs, intramuscular dosing and the Osmind partnership for software and site access could make it easier for mental health providers to adopt these treatments if they reach approval. At the same time, Cybin is still pre revenue, reporting a full year net loss of US$148 million and follow on equity raises that dilute shareholders. That mix of ambitious analyst forecasts, deep losses and ongoing trials makes upcoming data readouts an important focus for anyone tracking this stock.

Cybin’s late stage trials and deep reported losses create a story that feels incomplete. See how the analyst forecasts for Cybin stack up against those risks and what key assumption could change the whole picture.

Seeking Fresh Alternatives Beyond Psychedelics?

Fresh ideas move first. Stocks building quiet momentum can be flying under the radar for now. Spot potential breakouts before the crowd and act with a clear plan.

1. Look for early strength in companies with robust balance sheets before momentum is fully reflected in prices by scanning the curated list of solid balance sheet and fundamentals (50 results).
2. Combine potential income and price action by focusing on companies in the hand picked 12 dividend fortresses where yields and entry prices currently align.
3. Prepare for potential sector interest by reviewing the focused 54 AI infrastructure stocks that tracks businesses involved in building core AI hardware and networks.

Simply Wall St analyst Andrew Legget and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.